Trials / Recruiting
RecruitingNCT06905873
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Forte Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
Detailed description
Approximately 64 participants who meet all the screening eligibility criteria will be randomized to receive FB102 or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FB102 | Route of administration- Intravenous (IV) |
| DRUG | Placebo | Route of administration- Intravenous (IV) |
Timeline
- Start date
- 2025-03-25
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2025-04-02
- Last updated
- 2025-11-20
Locations
6 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT06905873. Inclusion in this directory is not an endorsement.